Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nanatinostat/valganciclovir combination therapy - Viracta Therapeutics

Drug Profile

Nanatinostat/valganciclovir combination therapy - Viracta Therapeutics

Alternative Names: CHR-3996; Nana-val; Tractinostat; Tractinostat-Viracta-Therapeutics; Valganciclovir/Nanatinostat combination therapy - Viracta Therapeutics; VRx-3996

Latest Information Update: 13 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chroma Therapeutics
  • Developer Chroma Therapeutics; Viracta Therapeutics
  • Class Amides; Antineoplastics; Antivirals; Hypoxanthines; Pyrimidines; Quinolines; Small molecules
  • Mechanism of Action Cytomegalovirus replication inhibitors; DNA-directed DNA polymerase inhibitors; Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral T-cell lymphoma; Plasmablastic lymphoma; Diffuse large B cell lymphoma; T-cell lymphoma; Post-transplant lymphoproliferative disorder; Nasopharyngeal cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lymphoma
  • Phase I/II Multiple myeloma; Nasopharyngeal cancer; Solid tumours
  • Phase I Cancer
  • No development reported Gastric cancer; Post-transplant lymphoproliferative disorder

Most Recent Events

  • 08 Mar 2024 Viracta Therapeutics plans a phase I trial for Cancer (Late-stage disease, Second-line therapy or greater) in Spain (PO, Tablets) (NCT06302140)
  • 01 Mar 2024 Phase-I clinical trials in Cancer (Late-stage disease, Second-line therapy or greater) in Spain (PO) (NCT06302140)
  • 29 Feb 2024 Viracta Therapeutics completes enrolment in phase II trial in Lymphoma in Australia, Brazil, Canada, France, Germany, Hong Kong, Israel, Italy, Malaysia, Singapore, South Korea, Spain, Taiwan, United Kingdom and USA (PO) (NCT05011058)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top